درباره این اپیزود
Drs Kathy D. Miller and Sara M. Tolaney discuss advancements and considerations for optimizing treatment for HER2-positive breast cancer, focusing on balancing efficacy with minimizing toxicity.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001124. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer https://pubmed.ncbi.nlm.nih.gov/25564897/
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer: Final 10-Year Analysis of the Open-Label, Single-Arm, Phase 2 APT Trial https://pubmed.ncbi.nlm.nih.gov/36858723/
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer https://pubmed.ncbi.nlm.nih.gov/30516102/
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/34077270/
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT https://pubmed.ncbi.nlm.nih.gov/38935923/
Treatment Discontinuation, Patient-Reported Toxicities and Quality-of-Life by Age Following Trastuzumab Emtansine or Paclitaxel/Trastuzumab (ATEMPT) https://pubmed.ncbi.nlm.nih.gov/36450763/
ATEMPT 2.0: Adjuvant T-DM1 vs TH https://clinicaltrials.gov/study/NCT04893109
Neoadjuvant Treatment With HER2-Targeted Therapies in HER2-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/35158791/
5-Year Analysis of Neoadjuvant Pertuzumab and Trastuzumab in Patients With Locally Advanced, Inflammatory, or Early-Stage HER2-Positive Breast Cancer (NeoSphere): A Multicentre, Open-Label, Phase 2 Randomised Trial https://pubmed.ncbi.nlm.nih.gov/27179402/
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy https://clinicaltrials.gov/study/NCT04266249
Alliance A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients With Residual HER2-Positive Invasive Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34636255/
Incidence of Interstitial Lung Disease and Cardiotoxicity With Trastuzumab Deruxtecan in Breast Cancer Patients: A Systematic Review and Single-Arm Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/37481956/
STOP-HER2: Stopping Trastuzumab in HER2+ MBC https://clinicaltrials.gov/study/NCT05721248
